Graft loss among renal-transplant recipients with early reduction of immunosuppression for BK viremia

被引:0
|
作者
Marwan M Azar [1 ,2 ]
Roland Assi [3 ]
Aziz K Valika
David B Banach [4 ]
Isaac E Hall [5 ]
Marie-Louise Landry [6 ]
Maricar F Malinis [2 ,3 ]
机构
[1] Department of Pathology,Section of Micro-biology,Massachusetts General Hospital
[2] Section of Infectious Dis-eases,Yale School of Medicine
[3] Department of Surgery,Yale University School of Medicine
[4] Division of Infectious Diseases,University of Connecticut School of Medicine  5. Division of Hypertension and Nephrology,University of Utah School of Medicine 
关键词
BK virus; Renal transplant; Screening; PyVAN; Prevention; Graft loss;
D O I
暂无
中图分类号
R699.2 [肾脏手术];
学科分类号
1002 ; 100210 ;
摘要
AIM To review the incidence of graft loss and acute rejection among renal transplant recipients with early reduction of immunosuppression for BK viremia.METHODS We performed a retrospective analysis of consecutive de-novo kidney-only transplants from January 2009 to December 2012 to evaluate the incidence of Polyomavirus associated nephropathy(PyV AN). Recipient plasma was screened for BKV DNA via quantitative polymerase chain reaction(PCR) at months 1,3,6,9 and 12 post-transplant and on worsening graft function.Immunosuppression was reduced at ≥ 3-log copies/mL. Those with viremia of ≥ 4-log copies/mL(presumptive PyV AN) underwent renal transplant biopsy. Presumptive Py VAN(PP) and definitive Py VAN(DP; biopsy-proven) were treated by immunosuppression reduction(IR) only. RESULTS Among 319 kidney transplant recipients,the median age was 53 years(range 19-83),65.8% were male,and 58.9% were white. Biopsy-proven acute rejection was found in 18.5% within 0-168 wk. Death-censored graft loss occurred in 5.3%(n = 17) and graft loss attributable to PyV AN was 0.6%(n = 2). Forty-seven patients were diagnosed with PP(14.7%) and 18(5.6%) with DP. Graft loss among participants with PyV AN(8.5%) and those without(4.8%) was not significantly different. Deceased donor kidney transplantation(OR = 2.3,95%CI = 1.1-4.6) and AR(OR = 2.3,95%CI = 1.2-4.7) were associated with Py VAN in the multivariate analysis. BK viremia between 3 and 4-log copies/mL occurred in 27 patients,all of whom underwent IR. Of these,16(59%) never developed PyV AN while 11(41%) developed PyV AN(4 DP,7 PP) within a range of 11-39 wk. CONCLUSION Instituting an early reduction of immunosuppression,in the absence of adjunctive antivirals,is effective at preventing PyV AN and may be associated with a lower incidence of graft-loss without a reciprocal increase in the incidence of acute rejection.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [1] Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
    Dvorai, R. Hod
    Lee, R.
    Muluhngwi, P.
    Raijmakers, M.
    Shetty, A.
    Tambur, A.
    Ison, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 454 - 455
  • [2] Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
    Dvorai, R. Hod
    Lee, R.
    Muluhngwi, P.
    Raijmakers, M.
    Shetty, A.
    Tambur, A.
    Ison, M.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 822 - 823
  • [3] Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
    Raijmakers, M.
    Shetty, A.
    Dvorai, R. Hod
    Tambur, A.
    Ison, M. G.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 984 - 984
  • [4] EFFECTIVENESS AND SAFETY OF AN IMMUNOSUPPRESSION REDUCTION PROTOCOL FOR THE TREATMENT OF BK VIREMIA IN KIDNEY TRANSPLANT RECIPIENTS
    Hebmann, D.
    Moreau, K.
    Garrigue, I.
    Couzi, L.
    Merville, P.
    Taton, B.
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 21 - 21
  • [5] Development of de novo donor-specific antibodies in renal transplant recipients with BK viremia managed with immunosuppression reduction
    Hod-Dvorai, Reut
    Lee, Ryan
    Muluhngwi, Penn
    Raijmakers, Mariella
    Shetty, Aneesha
    Tambur, Anat R.
    Ison, Michael G.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (01)
  • [6] BK viremia and nephropathy in pediatric renal transplant recipients
    Hamasaki, Yuko
    Dolan, Niamh M.
    Cubitt, David
    Breuer, Judith
    Sebire, Neil J.
    Marks, Stephen D.
    [J]. PEDIATRIC TRANSPLANTATION, 2019, 23 (05)
  • [7] Very early BK polyomavirus viremia is associated with graft dysfunction in kidney transplant recipients
    Fontana, Francesco
    Amurri, Alessio
    Alfano, Gaetano
    Donati, Gabriele
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1685 - I1687
  • [8] AN EXPECTANT REDUCTION IN IMMUNOSUPPRESSION IS AN EFFECTIVE MEANS OF REDUCING THE INDICENCE OF GRAFT FAILURE IN RENAL TRANSPLANT RECIPIENTS WITH BK NEPHROPATHY
    Goldsmith, Petra
    Siddagangaiah, Vishwanath
    Wong, Chang
    Ridgway, Dan
    Sharma, Ajay
    Mehra, Sanjay
    Howse, Matthew
    Middleton, Derek
    Lowe, David
    Christmas, Steve
    Hammad, Abdul
    [J]. TRANSPLANT INTERNATIONAL, 2015, 28 : 156 - 156
  • [9] WITHDRAWAL OF STEROID IMMUNOSUPPRESSION IN RENAL-TRANSPLANT RECIPIENTS
    STRATTA, RJ
    ARMBRUST, MJ
    OH, CS
    PIRSCH, JD
    KALAYOGLU, M
    SOLLINGER, HW
    BELZER, FO
    [J]. TRANSPLANTATION, 1988, 45 (02) : 323 - 328
  • [10] PSYCHIATRIC DISEASE AND CYTOMEGALOVIRUS VIREMIA IN RENAL-TRANSPLANT RECIPIENTS
    HIBBERD, PL
    SURMAN, OS
    BASS, M
    TOLKOFFRUBIN, NE
    COSIMI, AB
    SCHOOLEY, RT
    DORAN, M
    DELVECCHIO, A
    ROSAL, M
    RUBIN, R
    [J]. PSYCHOSOMATICS, 1995, 36 (06) : 561 - 563